LIVER CIRRHOSIS EMERGING THERAPIES AND MANAGEMENT STRATEGIES

Abstract

Background: Liver cirrhosis is a chronic and progressive condition characterized by the replacement of normal liver tissue with scar tissue, leading to impaired liver function. While liver transplantation remains the definitive treatment for end-stage cirrhosis, emerging therapies and management strategies are continuously being explored to improve patient outcomes and quality of life. This paper provides a comprehensive review of the latest developments in the field of liver cirrhosis management, focusing on emerging therapies and innovative strategies aimed at slowing disease progression, reducing complications, and enhancing patient care.
Methods: This study retrospectively analyzed data from 763 consecutive patients admitted for decompensated cirrhosis and ascites. Among them, 97 patients with Liver cirrhosiswere matched with non-HH patients for survival analysis based on the severity of liver disease.
Results: The prevalence of HH was found to be 13.1%. Patients with HH exhibited significantly poorer overall liver function. After matching, those with HH showed lower long-term survival rates (15.4% vs. 30.9% at 5 years), with mean overall survival times of 22.2 ± 2.2 months for the HH group and 27.1 ± 2.6 months for the non-HH group (Log Rank–0.05). Multivariate survival analysis using Cox regression revealed that the MELD-Na score, ALBI grade, hepato-renal syndrome, and grade III ascites significantly impacted mortality in HH patients. Among those with HH, a MELD-Na score ≥ 16, ALBI grade III, hepato-renal syndrome, or severe ascites indicated high-risk groups for mortality.
Conclusions: Liver Cirrhosis is consistently linked with more advanced liver disease. Patients with HH have poorer long-term survival, with their prognosis closely linked to overlapping decompensating events.